Phospholipid and Sphingolipid Composition of High-density Lipoproteins (HDL) in Obese Non-diabetic Patients With Metabolic Syndrome

Study Overview
=================
Brief Summary
-----------------
HDL in obese non-diabetic patients show major alterations in their function and thus their cardio-protective effects. These alterations could be explained by the quantitative and qualitative anomalies in the phospholipids and sphingolipids in the HDL. These molecules play a major role in HDL function and probably present early modifications in obesity, even before the onset of glycaemia deregulation. The aim of this study is to show the presence of qualitative and quantitative modifications of phospholipids and sphingolipids in HDL from obese patients compared with HDL from non-obese controls.

Official Title
-----------------
Phospholipid and Sphingolipid Composition of High-density Lipoproteins (HDL) in Obese Non-diabetic Patients With Metabolic Syndrome

Conditions
-----------------
Metabolic Syndrome

Intervention / Treatment
-----------------
* Biological: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged > 18 years fasting glycaemia < 1.10 g/l waist circumference > 102 cm for men and 88 cm for women (criteria NCEP/ATP III) 2 criteria among the following 3 (NCEP/ATP III criteria for metabolic syndrome): triglyceridaemia ≥ 1.50 g/l HDL cholesterol < 0.40 g/l for men and 0.50 g/l for women arterial blood pressure ≥ 130/85 mmHg or treatment for arterial hypertension patients who have provided written consent INCLUSION CRITERIA FOR HEALTHY SUBJECTS age > 18 years fasting glycaemia < 1.10 g/l waist circumference < 102 cm for men and 88 cm for women triglyceridaemia < 1.50 g/l HDL cholesterol ≥ 0.40 g/l for men and 0.50 g/l for women Healthy subjects who have provided written consent Exclusion Criteria: Persons without national health insurance cover Diabetes Diseases that interfere with lipoprotein metabolism (dysthyroidism not controlled with the treatment, kidney or liver disease) Treatments that interfere with lipoprotein metabolism (lipid-lowering agents, oestrogens, corticoids, retinoids, antiretroviral agents) Pregnancy/breast feeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Obese<br> | Biological: Blood sample<br> <br> |
| Placebo Comparator: control<br> | Biological: Blood sample<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in the mass percentages of total phospholipids + sphingolipids compared with the total HDL mass | in patients with abdominal obesity without hyperglycaemia compared with healthy controls | At inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in the percentage of each family of phospholipids or sphingolipids compared with total phospholipids + sphingolipids | in patients with abdominal obesity but without hyperglycaemia compared with healthy controls | At inclusion | 
| Difference in the percentage of each sub-family according to the nature of the fatty acids for phosphatidylcholines on the one hand and sphingomyelins on the other in patients | with abdominal obesity but without hyperglycaemia compared with healthy control | At inclusion |